MSD Korea acquired an approval for its anti PD-1 antibody from the Ministry of Food and Drug Safety
“We will represent changes of the paradigm with our 3rd generation anticancer drug overcoming side effects of systemic cancer chemotherapy and tolerance risks of targeted argents.”
MSD Korea (CEO Dong-wook Hyun) acquired the first approval for its anti PD-1 antibody, Keytruda TM (pmbrolizumab), ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
